Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer

PURPOSE: We incorporated cetuximab, a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR), into the induction therapy and subsequent chemoradiotherapy of head and neck cancer (HNC). PATIENTS AND METHODS: Patients with locally advanced HNC, including squamous and undiffer...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Argiris, Athanassios, Heron, Dwight E., Smith, Ryan P., Kim, Seungwon, Gibson, Michael K., Lai, Stephen Y., Branstetter, Barton F., Posluszny, Donna M., Wang, Lin, Seethala, Raja R., Dacic, Sanja, Gooding, William, Grandis, Jennifer R., Johnson, Jonas T., Ferris, Robert L.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2010
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3018361/
https://ncbi.nlm.nih.gov/pubmed/21079141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.6423
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items